Drug Profile
HIV vaccine - Institute of Human Virology/Profectus Biosciences
Alternative Names: AIM Therapy - Profectus BioScience; anti-HIV antibodies - Profectus BioScience; FLSC vaccine; Full-length single chain vaccine; IHV 001; IHV 01Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Profectus Biosciences
- Developer Institute of Human Virology; Profectus Biosciences
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 08 Dec 2020 U.S. Army Medical Research and Development Command plans a phase I trial for HIV infections (Prevention, Combination therapy, In adults, In the elderly) in March 2021 in Thailand (IM) (NCT04658667)
- 28 Nov 2018 No recent reports of development identified for phase-I development in HIV-infections(Prevention, In volunteers) in USA (Parenteral)
- 01 Jul 2018 Institute of Human Virology, in collaboration with Profectus Biosciences completes a phase I trial in HIV infections (In volunteers, Prevention) in USA (IM) (NCT02756208)